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L-dopa induced dyskinesia (LID) is a debilitating side-effect of the primary treatment 
used in Parkinson’s disease (PD), l-dopa. Here we investigate the effect of HU-308, 
a cannabinoid CB2 receptor agonist, on LIDs. Utilizing a mouse model of PD and 
LIDs, induced by 6-OHDA and subsequent l-dopa treatment, we show that HU-308 
reduced LIDs as effectively as amantadine, the current frontline treatment. 
Furthermore, treatment with HU-308 plus amantadine resulted in a greater anti-
dyskinetic effect than maximally achieved with HU-308 alone, potentially suggesting 
a synergistic effect of these two treatments. Lastly, we demonstrated that treatment 
with HU-308 and amantadine either alone, or in combination, decreased striatal 
neuroinflammation, a mechanism which has been suggested to contribute to LIDs. 
Taken together, our results suggest pharmacological treatments with CB2 agonists 
merit further investigation as therapies for LIDs in PD patients. Furthermore, since 
CB2 receptors are thought to be primarily expressed on, and signal through, glia, our 
data provide weight to suggestion that neuroinflammation, or more specifically, 
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1. Introduction 1 
Parkinson’s disease (PD) is a neurodegenerative disorder caused by the progressive 2 
loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and their 3 
projections into the striatum. As PD progresses dopamine availability decreases, 4 
leading to the characteristic locomotor deficits including tremors, rigidity and 5 
bradykinesia (Chaudhuri et al., 2006). For several decades dopamine replacement 6 
therapy with l-dopa has been the gold-standard treatment for combating the motor 7 
symptoms for patients with PD. However, as disease progresses, l-dopa doses often 8 
need to be increased in order to manage symptoms. Approximately 52-78% of 9 
patients may in turn develop debilitating l-dopa induced dyskinesias (LIDs), classified 10 
as abnormalities or impairments of voluntary movements, within 10 years of initiating 11 
treatment (Manson et al., 2012). Accordingly, LIDs present a clinical-therapeutic 12 
conundrum, as the appearance of LIDs prevents further increasing l-dopa doses and 13 
in fact often needs to be managed by lowering l-dopa doses, which in turn leads to 14 
the loss of l-dopa’s anti-parkinsonian efficacy (Pandey and Srivanitchapoom, 2017). 15 
 16 
To date, the only FDA approved therapy to combat LIDs in PD patients is 17 
amantadine. The clinical use of amantadine is unfortunately limited by several side 18 
effects, the development of tolerance and a lack of efficacy in some patients (Perez-19 
Lloret and Rascol, 2018; Sharma et al., 2018). For this reason, there is a great 20 
unmet clinical need for new therapies to treat LIDs.  21 
 22 
In order to develop new therapies for LIDs, it is necessary to target the underlying 23 
mechanisms. Amantadine has been thought to exert its beneficial effects through its 24 




2012), while recent research has intriguingly identified amantadine’s effects on glia 26 
as a potential mechanism (Kim et al., 2012; Ossola et al., 2011). More generally, 27 
while there is no consensus, synapse loss and pathological regrowth (Fieblinger et 28 
al., 2014; Suárez et al., 2014; Zhang et al., 2013), changes in synaptic plasticity 29 
(Picconi et al., 2003; Thiele et al., 2014) and neuroinflammation (Mulas et al., 2016), 30 
have all been implicated in LID pathogenesis. Given the growing understanding of 31 
the enumerate roles of glia in the healthy and diseased brain (Hammond et al., 2018; 32 
Khakh and Sofroniew, 2015; Morris et al., 2013) including LIDs (Mulas et al., 2016), 33 
targeting neuroinflammation, or perhaps more specifically glial signaling, provides a 34 
potential strategy for pre-clinical and clinical drug development for LIDs.   35 
 36 
If targeting neuroinflammation, and or glial signaling, offers a potential strategy, then 37 
cannabinoid based therapies could be an option for treating LIDs. Cannabinoid-38 
based therapies can exert effects on glia, are thought to suppress 39 
neuroinflammation, and have neuroprotective effects in preclinical animal models of 40 
several neurodegenerative disorders (Bisogno and Di Marzo, 2010). Intriguingly, 41 
some observational studies have indicated that smoking medical cannabis can 42 
alleviate LID in PD patients (Finseth et al., 2015; Lotan et al., 2014; Venderová et al., 43 
2004). Cannabinoid effects are primarily mediated through the cannabinoid receptors 44 
CB1 and CB2 and previous preclinical studies have demonstrated that CB1 agonists 45 
(dos-Santos-Pereira et al., 2016; Ferrer et al., 2003; Fox et al., 2002; Martinez et al., 46 
2012; Morgese et al., 2007; Song et al., 2014; Walsh et al., 2010) exert anti-47 
dyskinetic properties. In contrast, the therapeutic potential of exclusively targeting 48 





While CB2 selective agonists have not been investigated, they could be of particular 51 
clinical relevance, as it is suggested that targeting this receptor does not provoke the 52 
psychoactive side-effects associated with CB1 receptor activation (Pacher et al., 53 
2006). Moreover, in the brain CB2 receptors are thought to be predominantly 54 
expressed by microglia (Jordan and Xi, 2019; Palazuelos et al., 2009) and astrocytes 55 
(Fernández-Trapero et al., 2017). Further, while CB2 expression in the healthy brain 56 
is relatively low, expression in glia is elevated in preclinical animal models of 57 
neurodegenerative diseases as well as in human brain tissue of Parkinson’s 58 
(Gómez-Gálvez et al., 2016), Huntington’s (Palazuelos et al., 2009) and Alzheimer’s 59 
disease patients (Benito et al., 2003). One intriguing interpretation of this is that CB2 60 
expression is upregulated as part of a glial homeostatic response. In support of this, 61 
CB2 receptor activation appears to initiate a signalling cascade in glia leading to 62 
decreased pro-inflammatory cytokine production and decreased glial cell-63 
proliferation (Ashton and Glass, 2007). These effects are hypothesised to contribute 64 
to neuroprotection in various toxin based rodent models of PD including rotenone 65 
(Javed et al., 2016), MPTP (Price et al., 2009) and LPS (Gómez-Gálvez et al., 2016). 66 
Thus, pharmacologically stimulating CB2 receptor signalling may be a promising 67 
therapeutic strategy for neurodegenerative conditions where neuroinflammation, and 68 
therefore altered glial responses (Ben Haim et al., 2015; Booth et al., 2017; Morris et 69 
al., 2013; Priller and Prinz, 2019), are implicated.  70 
 71 
Collectively, the apparent potential of cannabinoid therapies for treatment of several 72 
neurological conditions (Benito et al., 2003; Gómez-Gálvez et al., 2016; Palazuelos 73 
et al., 2009), the putative relationship of neuroinflammation in LID pathogenesis 74 




properties (Gómez-Gálvez et al., 2016; Javed et al., 2016; Price et al., 2009), all 76 
point to CB2 receptors as a promising therapeutic target for dyskinesia. Thus, in the 77 
current study, we hypothesized that a CB2 receptor agonist may exert anti-dyskinetic 78 
efficacy in a mouse model of LID.  79 
 80 
To test this hypothesis, we utilized the selective CB2 receptor agonist HU-308 81 
(Hanus et al., 1999). HU-308 treatment has previously been shown to reduce 82 
microglia proliferation and cytokine expression and provide concurrent 83 
neuroprotection in mouse models of Parkinson’s (Gómez-Gálvez et al., 2016) and 84 
Huntington’s disease (Palazuelos et al., 2009). We aimed to determine if the putative 85 
actions of HU-308 on glia could also translate into an effect on LIDs created by 86 
repeat l-dopa treatment in a 6-OHDA mouse model of PD. We also investigated the 87 
potential anti-dyskinetic effect of HU-308 alone and in combination with amantadine, 88 
as well as their effects on glial reactivity in striatal tissue of 6-OHDA lesioned mice 89 
expressing LIDs. 90 
 91 
2. Material and methods 92 
2.1 Animals 93 
Male C57BL/6j mice aged 7-11 weeks were obtained from Australian BioResources 94 
(Mona Vale, Australia) and were allowed to acclimatize for one week prior to study 95 
commencement. Mice were housed at a maximum five mice per cage, until the study 96 
began, at which time mice were housed individually. Mice were kept on a 12-hour 97 
light/dark cycle with access to food and water ad libitum. All animal experiments 98 
were performed with the approval of the Garvan Institute and St. Vincent’s Hospital 99 




with National Health and Medical Research Council animal experimentation 101 
guidelines and the Australian Code of Practice for the Care and Use of Animals for 102 
Scientific Purposes (2004). All surgeries were performed under ketamine/xylazil 103 
anaesthesia, and all efforts were made to minimize suffering.  104 
 105 
2.2 Unilateral medial forebrain bundle (MFB) lesioning 106 
Thirty minutes prior to surgery desipramine hydrochloride (Sigma Aldrich) was 107 
administered at 10 ml/kg by intra-peritoneal (i.p.) injection. Animals were then 108 
anaesthetized with a mixture of ketamine (8.7 mg/ml; Mavlab) and xylazil (2 mg/ml; 109 
Troy Laboratories Pty Ltd) and placed in stereotaxic apparatus (Kopf Instruments). 110 
Mice were then injected with 0.2 μl of 15 mg/ml (total 3 μg) of 6-hydroxydopamine 111 
hydrobromide (Sigma Aldrich) in 0.02% ascorbic acid in the right MFB at the 112 
following coordinates: AP -1.2, ML -1.1, DV -5.0, relative to bregma and the dural 113 
surface, as previously described (Rentsch et al., 2019; Thiele et al., 2012). 6-OHDA 114 
(or 0.02% ascorbic acid control) was injected at a rate of 0.1 μl/minute and the 115 
syringe was left in place for 5 minutes following each injection to allow for complete 116 
diffusion into the target area. The incision was sutured (Dynek) and animals were 117 
placed in individual cages on heating pads. During post-operative recovery, mice 118 
were provided with recovery gels and sugared milk to ensure adequate nutrition and 119 
hydration. One half of the cage was kept on heading pads for the entire study, to 120 
allow mice to choose their environment and to preclude hypothermia. Mice were 121 
monitored daily for three weeks following surgery and were injected subcutaneously 122 
with 300 μl glucose (5%) and 300 μl saline (0.9%) (Schuler et al., 2009) if signs of 123 





2.3 Cylinder test 126 
Mice were placed into a clear circular cylinder (diameter 15cm) on three occasions 127 
(prior to 6-OHDA lesion surgery, 3 weeks post 6-OHDA lesion surgery, 3 weeks and 128 
1 day post 6-OHDA lesion surgery after receiving initial treatment and l-dopa 129 
injection) and the first 20 paw placements of the left or right paw on the cylinder wall 130 
were scored. Only full juxtapositions of the paw to the cylinder wall were counted that 131 
served the purpose of supporting the animal’s body weight. The total forelimb bias 132 
was determined by calculating the number of wall contacts made with the impaired 133 
paw (left) as a percentage of total contacts. The cylinder was cleaned with 70% 134 
ethanol between animals. 135 
 136 
2.4 Abnormal involuntary movements (AIMs) 137 
Mice were co-administered with l-dopa methyl ester (6 mg/kg; Sigma Aldrich, in 138 
saline i.p.) and benserazide-HCl (12.5 mg/kg; Sigma Aldrich, in saline i.p.) to induce 139 
abnormal involuntary movements (AIMs) as described in the experimental design. 140 
AIMs were evaluated according to the mouse dyskinesia scale described in detail 141 
previously (Cenci and Lundblad, 2007; Rentsch et al., 2019; Sebastianutto et al., 142 
2016). Briefly, mice were placed individually in transparent plastic cylinders 143 
(diameter 15 cm) without bedding material and scored for 1 min every 20th min 144 
during the 120 min following l-dopa administration. The AIMs were classified into 145 
three subtypes according to their topographic distribution. Axial AIMs were 146 
characterized by twisting motions of the neck and upper trunk towards the 147 
contralateral side of the lesion. Limb AIMs are rapid uncontrolled movements 148 
or dystonic posturing of the contralateral forelimb and orolingual AIMs are 149 




were scored on two different parameters simultaneously on a scale of 1-4 (with 4 151 
being the highest) based on the severity (amplitude scale) and the amount of time 152 
they are present (basic scale). A total AIM score was then produced by multiplying 153 
basic score and amplitude score for each AIM subtype, at each monitoring period, 154 
and the sum of these scores is referred to as “global AIMs”.  155 
 156 
2.5 Immunohistochemistry  157 
Brains were harvested and processed as described in detail previously (Stayte et al., 158 
2015). 40 μm coronal brain sections were blocked with 3% BSA + 0.25% Triton-X-159 
100 and then incubated in the following primary antibodies: polyclonal rabbit ionized 160 
calcium binding adaptor molecule 1 (IBA1, 1:1000 Novachem, cat # 019-19741), 161 
monoclonal mouse glial fibrillary acidic protein (GFAP 1:500, Cell signalling, cat # 162 
3670) monoclonal mouse tyrosine hydroxylase (TH, 1:1000 Sigma Aldrich, cat # 163 
T2928), or polyclonal rabbit anti-TH (1:1000, Merck Millipore, cat # AB152) for 72 164 
hours at 4°C. All sections were then incubated in their respective secondary 165 
antibodies (1:250, Invitrogen, cat # A11029, A11008, A21236, A21245) overnight at 166 
4°C followed by a counterstain with 4’,6-diamidino-2-phenylindole (DAPI; Life 167 
Technologies). Finally, sections were mounted onto SuperFrost-plus slides (Menzel-168 
Glaser) and coverslipped with 50% glycerol mounting medium (Merck).  169 
 170 
2.6 Stereology 171 
Striatal cell populations were quantified using the optical fractionator method and 172 
Stereo Investigator 7 software (MBF Bioscience), as previously described (Stayte et 173 
al., 2015). For estimations of IBA1 positive populations a counting frame of 100 μm x 174 




GFAP positive populations a counting frame of 120 μm x 120 μm and a grid size of 176 
300 μm x 300 μm was used. For all cell types the guard zone height used was 5 μm 177 
and dissector height used was 10 μm, with every 12th section sampled to a total of 7 178 
sections. Coefficient of error attributable to the sampling was calculated according to 179 
Gundersen and Jensen (Gundersen and Jensen, 1987). Errors ≤0.10 were regarded 180 
as acceptable. The striatum was delineated from -1.53 to 1.35 mm relative to 181 
bregma based on the Paxinos atlas for the mouse brain and divided into two 182 
subregions, the dorsal-lateral and ventral-medial striatum (Paxinos and Franklin, 183 
2001). In order to ensure that differences in glial counts did not originate from 184 
differences in tracing volume these data are presented as number of cells per area 185 
instead of absolute numbers. 186 
 187 
2.7 Capillary western blotting (Wes)  188 
Striatal tissue homogenates and protein quantification were performed as previously 189 
described (Stayte et al., 2017). Western blotting analysis was performed using the 190 
capillary automated Wes system (ProteinSimple). Using the Wes12–230kDa 191 
separation module (ProteinSimple, SM-W004) samples were prepared according to 192 
manufacturer’s instructions and the following primary antibodies were utilized: 193 
monoclonal mouse FosB (1:100 Abcam, cat # ab11959), polyclonal rabbit anti-TH 194 
(1:1000, Merck Millipore, cat # AB152), monoclonal rabbit nuclear factor kappa-light-195 
chain-enhancer of activated B cells (NF-κB, 1:100 Cell signalling, cat # 4764), 196 
monoclonal rabbit NF-κB (Ser536) (1:10 Cell signalling, cat # 3033), monoclonal 197 
mouse beta-tubulin (1:1000 Promega, cat # G712A) and monoclonal mouse 198 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 1:5000 Abcam, cat # 199 




001) or the anti-mouse detection module (ProteinSimple, DM-002) was used and for 201 
multiplexing the concentrated 20x anti-rabbit (ProteinSimple, 043426) was used in 202 
combination with the anti-mouse detection module. Data were analysed using the 203 
Compass software and peak area measurements were obtained for the protein of 204 
interest and normalized to the biological loading control.  205 
 206 
2.8 Bead based immune assay 207 
Using the same striatal tissue sample as for the western blotting analysis, tumor 208 
necrosis factor alpha (TNFα), interleukin-1beta (IL-1β), interleukin-6 (IL-6) and 209 
interleukin-10 (IL-10) cytokine levels were quantitatively measured by the BD 210 
cytometric bead array mouse enhanced Kit (BD Bioscience). The operations were 211 
performed according to the manufacturer’s instructions utilizing a LSR-II flow 212 
cytometer (Becton Dickinson) with FACSDiva software and FCAP array software. 213 
 214 
2.9 Statistics 215 
All statistical analyses were performed using IBM SPSS Statistics version 25 (SPSS 216 
Inc.) or Prism 6 (GraphPad). Shapiro-Wilk tests were performed on all data sets to 217 
assess normality, before analysing data either with parametric or non-parametric 218 
tests. For normally distributed data, differences between means were assessed, as 219 
appropriate, by one- or two- way ANOVA with or without repeated measures, 220 
followed by Bonferroni post hoc analysis. All data is presented as mean ± standard 221 
error of the mean (SEM). For all statistical tests, a p value of ≤ 0.05 was assumed to 222 






2.10 Experimental design 226 
Beginning three weeks following 6-OHDA lesion surgery animals received repeated 227 
l-dopa and benserazide injections over a three week period. During the final week 228 
AIMs were scored on two occasions (Pretest). Animals that failed to develop AIMs 229 
(global AIMs score below 40) or that, post study, had an insufficient lesion (less than 230 
60% loss of TH in ipsilateral striatum when compared to contralateral hemisphere) 231 
were excluded from the study. Based on the AIM scores of the two testing sessions 232 
animals were equally divided into treatment groups. Beginning the day after the last 233 
pretest animals started to receive daily i.p treatment injections (40mg/kg amantadine 234 
(Sigma Aldrich); 1mg/kg, 2.5mg/kg or 5mg/kg HU-308 (Tocris); 1mg/kg SR144528 235 
(Sigma Aldrich)). All drugs were dissolved in Tween 80 and dimethyl sulfoxide 236 
(DMSO), and then diluted in saline (Tween 80:DMSO:saline = 1:1:18). 30 min after 237 
treatment injections animals were injected with l-dopa and benserazide. AIM 238 
expression was measured every third day for a total of five testing sessions. On the 239 
day after the last AIM scoring session animals received a final l-dopa/benserazide 240 
injection and tissue was collected 1h later (Fig. 1A). For all immunohistochemical 241 
experiments animals were anaesthetized via a ketamine/xylazil mixture before 242 
cardiac perfusion with 4% paraformaldehyde. For all other analyses animals were 243 
anaesthetized via isofluorane followed by cervical dislocation and rapid tissue 244 
collection. The experimenter was at all times blinded to group assignment and 245 
outcome assignment in every experiment performed and tissue collection and 246 
processing was performed in appropriate blocks. All experiments were performed in 247 





Figure 1: Experimental design. (A) Timeline of the study. (B) List of experiments 250 
performed, including the number of trials, respective mortality, the number of animals 251 
excluded from the study and the number of animals per treatment group used for 252 
behavioural and molecular analysis.  253 
 254 
 255 
3. Results 256 
 257 
3.1 A CB2 agonist, HU-308, has a behavioural effect on LIDs  258 
3.1.1 HU-308 dose-dependently decreased the severity of LID in mice 259 
HU-308 has previously been shown to exert its anti-inflammatory and 260 
neuroprotective effects in rodent models of Parkinson’s (Gómez-Gálvez et al., 2016) 261 




dose as a starting point, we first intended to test the dose-dependent efficacy of HU-263 
308 on reducing established AIMs in 6-OHDA lesioned mice. 264 
 265 
A two-way repeated measures ANOVA revealed a significant interaction 266 
(F(12,224)=3.546, p<0.001; Fig. 2A) between dosage and time point, indicating a dose 267 
dependent effect that changes over time. The simple effect was significant for dose 268 
(F(3,56)=10.49, p<0.001) and time (F(4,224)=17.63, p<0.001). Post hoc analysis 269 
revealed that 2.5mg/kg (day 1 – day 13 p<0.001) and 5mg/kg (day 1 – day 10 270 
p<0.001; day 13 p<0.01) significantly reduce AIMs when compared to the control at 271 
each time point. In contrast the 1mg/kg dose only showed a trend towards reduction 272 
of AIMs, but no sustained statistically significant anti-dyskinetic effect over the 273 
course of treatment. Collectively, our behavioural results indicate an anti-dyskinetic 274 
effect of 2.5mg/kg and 5mg/kg HU-308, with the maximal effect not increasing 275 
beyond that seen at 2.5mg/kg. Importantly, this anti-dyskinetic effect of HU-308 did 276 
not occur at the expense of the anti-parkinsonian efficacy of l-dopa, as forelimb use 277 
asymmetry, evaluated using the cylinder test (Schallert et al., 2000), was improved 278 
by l-dopa alone or when co-administered with HU-308 (t-test: Pre-lesion p=0.2936; 279 
6-OHDA lesion p=0.7885; 6-OHDA lesion + 1. L-Dopa p>0.9999; Fig. 2B). 280 
 281 
Molecular analysis of FosB, a protein widely used as a molecular marker of LIDs 282 
(Andersson et al., 1999; Winkler et al., 2002), largely confirmed our behavioural 283 
findings. A one-way ANOVA revealed a significant reduction of striatal FosB 284 
expression following HU-308 treatment (F(3,32)=12.74, p<0.001; Fig. 2C). Bonferroni 285 
post hoc analysis indicated a similar reduction of FosB expression for 1mg/kg 286 




compared to control. Lastly, to rule out the possibility of different lesion sizes to 288 
explain any anti-dyskinetic effects, we quantified TH protein levels in both the 289 
lesioned and non-lesioned striatum. A two-way ANOVA of hemisphere and treatment 290 
on TH expression revealed that all mice had a similar unilateral lesion size that was 291 
not affected by treatment regime (interaction F(3,64)=0.3106, p=0.8176, hemisphere 292 
F(1,64)=384.6, p<0.001, treatment F(3,64)=0.3372, p=0.7984; Fig. 2D). Collectively, 293 
these results indicate 2.5mg/kg HU-308 as the lowest effective dose exerting a 294 
behavioural anti-dyskinetic effect that is supported with a reduction in FosB 295 
expression. Given there was no increased benefit of 5mg/kg HU-308, the 2.5mg/kg 296 





Figure 2: HU-308 dose-dependently attenuates LIDs. (A) Systemic treatment with 299 
2.5mg/kg and 5mg/kg HU-308 produced a significant reduction in global AIM scores 300 
over the entire testing period of 13 days, whereas 1mg/kg HU-308 alleviated AIMs 301 
on the first day with only a trend to effect seen subsequently when compared to the 302 
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not affect the anti-parkinsonian efficacy of L-Dopa treatment (n = 5 per group). 304 
Western blotting analysis revealed (C) reduced FosB expression in the ipsilateral 305 
striatum at every dose when compared to the control and (D) TH expression was 306 
consistently reduced in the ipsilateral striatum when compared to the contralateral 307 
hemisphere at every dose (n = 9 per group). All values represent the mean ± SEM. 308 
** = p < 0.01, *** = p <0.001 compared to control; ### = p < 0.001 compared to 309 
contralateral hemisphere.  310 
 311 
3.1.2 The anti-dyskinetic effect of HU-308 can be eliminated with a CB2 312 
antagonist 313 
After establishing that HU-308 reduced LID severity we next aimed to investigate the 314 
CB2 receptor specificity of this effect. To determine this in the following experiment 315 
we co‐administered HU‐308 with the selective CB2 receptor antagonist SR144528 316 
(Hanus et al., 1999), to determine whether this could block the anti-dyskinetic effect 317 
of HU‐308. Furthermore we analysed the effect of CB2 antagonism on LIDs, alone.  318 
 319 
A two-way repeated measures ANOVA revealed no significant interaction 320 
(F(12,144)=0.536, p=0.8883; Fig. 3A) between treatment and time point, with no main 321 
effect of time (F4,144)=2.354, p=0.0567), but a significant effect of treatment 322 
(F(3,36)=33.02, p<0.001). Post-hoc analysis confirmed the ability of HU-308 (p<0.001) 323 
to significantly reduce AIMs, as reported above. SR144528 (p>0.999) had no effect 324 
on AIMs when administered alone, however when mice were treated with HU-308 325 
and SR144528 conjointly, SR144528 abolished the anti-dyskinetic effect of HU-308 326 




data are strongly supported with the molecular analysis of FosB protein in striatal 328 
tissue. A one way ANOVA revealed a significant effect of FosB expression 329 
(F(3,28)=3.951, p<0.05; Fig. 3B). Bonferroni post-hoc analysis indicated a reduction of 330 
FosB expression in HU-308 treated animals (p<0.05) however this effect was lost in 331 
animals that were co-administered with HU-308 and SR144528. In summary, these 332 
behavioural and molecular results indicate the importance of CB2 signalling in the 333 
anti-dyskinetic effect of HU-308. Lastly, a two-way ANOVA of hemisphere and 334 
treatment on TH expression confirmed that all mice had a stable unilateral lesion that 335 
was not affected by treatment regime (interaction F(3,56)=3.399 p=0.0239, 336 





Figure 3: SR144528 blocks the anti-dyskinetic effect of HU-308. The efficacy of 339 
HU-308 (2.5mg/kg) on reducing (A) AIMs (n = 10 per group) and (B) FosB 340 
expression (n = 8 per group) is inhibited when co-administered with the CB2 341 
antagonist SR144528 (1mg/kg). (C) TH expression was consistently reduced in the 342 
ipsilateral striatum when compared to the contralateral hemisphere with every 343 
treatment (n = 8 per group). All values represent the mean ± SEM. * = p < 0.05, *** = 344 
p <0.001 compared to control; ### = p < 0.001 compared to contralateral 345 
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3.1.3 The combined treatment of HU-308 and amantadine resulted in an 348 
additive anti-dyskinetic effect 349 
Next we aimed to compare the magnitude of the anti-dyskinetic effect of HU-308 to 350 
that of amantadine. We also aimed to investigate the possibility of an additive anti-351 
dyskinetic effect of amantadine and HU-308 co-treatment.  352 
 353 
A two-way repeated measures ANOVA revealed no significant interaction 354 
(F(12,176)=0.9064, p=0.5418; Fig. 4A) between treatment and time, with a minor main 355 
effect of time (F(4,176)=2.484, p<0.05) and a strong significant effect of treatment 356 
(F(3,44)=28.34, p<0.001). Post-hoc analysis indicated that HU-308 treatment 357 
(p<0.001) was as effective as amantadine (p<0.001) in reducing AIMs when 358 
compared to the control. Strikingly, the combined treatment of amantadine and HU-359 
308 was not only significantly more effective than the control (p<0.001), but also 360 
more effective than the individual amantadine (p<0.01) and HU-308 (p<0.01) 361 
treatment groups. This may suggest a synergistic effect of the combined treatment 362 
regime. 363 
 364 
Next, we performed a detailed analysis of individual time points on the first day (Day 365 
43) and the last day (Day 55) of treatment, in order to elucidate if these treatment 366 
regimes shorten the time or reduce the severity of AIMs expression. Two-way 367 
repeated measures ANOVAs revealed significant interaction (Day 43: F(15,220)=5.376, 368 
p<0.001; Day 55: F(15,220)=4.385, p<0.001; Fig. 2B/C) between treatment and time. 369 
Therefore the simple effects were analysed and were significant for time (Day 43: 370 




F(3,44)=21.45, p<0.001; Day 55: F(3,44)=18.5, p<0.001). Post-hoc analysis revealed 372 
that all treatments reduced the severity of AIMs at peak LID (20-80min) when 373 
compared to the control and combined treatment of amantadine and HU-308 was 374 
more effective than the individual amantadine and HU-308 treatment groups, further 375 
favouring the hypothesis of a synergistic effect.   376 
 377 
Additionally, a one way ANOVA of FosB expression revealed a significant effect 378 
(F(3,28)=8.821, p<0.001; Fig. 4D), supporting our behavioural findings. Bonferroni 379 
post-hoc analysis indicated a reduction of FosB expression in amantadine (p<0.001), 380 
HU-308 (p<0.01) and amantadine + HU-308 (p<0.01) when compared to control. 381 
Lastly, a two-way ANOVA of hemisphere and treatment on TH expression revealed 382 
that all mice had a stable unilateral lesion that was not affected by treatment regime 383 
(interaction F(3,56)=0.4353 p=0.7286, hemisphere F(1,56)=735.9, p<0.001, treatment 384 








Figure 4: Treatment with amantadine plus HU-308 results in an additive anti-387 
dyskinetic behavioural effect. Systemic treatment with amantadine (40mg/kg) and 388 
HU-308 (2.5mg/kg) resulted in a similar reduction in global AIM scores and conjoint 389 
treatment enhanced this anti-dyskinetic effect (n = 12 per group) over (A) five testing 390 
sessions and  during each monitoring session on (B) day 43 and (C) day 55. 391 
Western blotting analysis revealed (D) reduced FosB expression in the ipsilateral 392 
striatum with every treatment regime when compared to the control (n = 8 per group) 393 
and (E) TH expression was consistently reduced in the ipsilateral striatum when 394 
compared to the contralateral hemisphere with every treatment (n = 8 per group). All 395 
values represent the mean ± SEM. ** = p < 0.01, *** = p < 0.001 compared to 396 
control; + = p < 0.05, ++ = p < 0.01, +++ = p < 0.001 compared to amantadine; ^ = p 397 
< 0.05, ^^ = p < 0.01, ^^^ = p < 0.001 compared to HU-308;  ### = p < 0.001 398 
compared to contralateral hemisphere.   399 
 400 
3.2 Both HU-308 and amantadine reduce neuroinflammation in the striatum of 401 
dyskinetic mice 402 
Having established a robust anti-dyskinetic effect of amantadine and HU-308 403 
treatment we next aimed to investigate a possible underlying mechanism. Both 404 
amantadine (Kim et al., 2012; Ossola et al., 2011) and HU-308 (Gómez-Gálvez et 405 
al., 2016; Palazuelos et al., 2009) have previously been reported to reduce pro-406 
inflammatory markers as well as reducing glial proliferation. Since 407 
neuroinflammation, which is associated with changes in glial morphology and 408 
signalling, has previously been linked to LIDs (Mulas et al., 2016), we aimed to 409 
investigate if our treatment regimes influence glial proliferation and 410 




3.2.1 Amantadine and HU-308 reduce microglia and astrocyte populations in 412 
the striatum of 6-OHDA lesioned mice 413 
As some research indicates the dorsal-lateral striatum as the most important striatal 414 
subregion associated with changes in LIDs (Fasano et al., 2010; Girasole et al., 415 
2018; Pavón et al., 2006), we set out to assess if HU-308 and/or amantadine 416 
reduced microglial and astrocyte populations in the dorsal-lateral and ventral-medial 417 
striatum. 418 
 419 
To quantify microglial numbers we counted IBA1 positive cells, a widely used marker 420 
to label microglia populations. One-way ANOVA analyses revealed significant 421 
differences of IBA1 positive cells between treatment groups in the dorsal-lateral 422 
(F(3,20)=7.317, p<0.01; Fig. 5B) and ventral-medial (F(3,20)=15.66, p<0.001; Fig. 5C) 423 
striatum. Post hoc analyses demonstrated that IBA1 positive cells were decreased in 424 
amantadine (DL: p<0.05; VM: p<0.001), HU-308 (DL: p<0.01; VM: p<0.001) and 425 
amantadine + HU-308 (DL: p<0.05; VM: p<0.001) treated mice, when compared to 426 
control mice. Accordingly, all treatments tested in this study were able to reduce 427 
microglia numbers in the striatum.  428 
 429 
Next, we aimed to identify if the treatment dependent decrease in microglia is 430 
accompanied by a decrease in astrocytes. Therefore we counted GFAP positive 431 
cells, a marker traditionally used to label astrocyte populations under inflammatory 432 
conditions. One-way ANOVA analysis revealed significant differences of GFAP 433 
positive cells between treatment groups in the dorsal-lateral (F(3,20)=11.84, p<0.001; 434 
Fig. 5E) and the ventral-medial (F(3,20)=3.993, p<0.05; Fig. 5F) striatum. Post hoc 435 




p<0.01), HU-308 (DL: p<0.001) and amantadine + HU-308 (DL: p<0.001; VM: 437 
p<0.05) treated mice, when compared to control mice. Accordingly, all treatments 438 
tested in this study were able to reduce astrocyte numbers predominantly in the 439 








































































































































































































Figure 5: Amantadine and HU-308 treatment regimes reduce microglia and 442 
astrocyte populations in the striatum of LID mice. Representative images for (A) 443 
IBA1+ and (D) GFAP+ cells in the ipsilateral striatum of different treatment groups. 444 
Stereological quantification demonstrated amantadine, HU-308, and amantadine + 445 
HU-308 treatments decreased IBA1+ cell counts in the (B) dorsal-lateral and (C) 446 
ventral-medial striatum and GFAP+ cell counts in the (E) dorsal-lateral and (F) 447 
ventral-medial striatum. All values represent the mean ± standard error of the mean 448 
(SEM). *** = p < 0.001, ** = p < 0.01, * = p < 0.05 compared to control group (n = 6 449 
per group). Scale bar represents 50μm 450 
 451 
3.2.2 Amantadine, HU-308 and combined treatment decreased cytokine 452 
expression in the striatum of dyskinetic mice 453 
In addition to increasing in numbers, under inflammatory conditions microglia and 454 
astrocytes also upregulate their production of an array of cytokines. Accordingly, we 455 
next aimed to determine if amantadine, HU-308, and conjoint treatment can reduce 456 
the amount of pro-inflammatory cytokines (TNFα, IL-1β, IL-6) and/or alter an anti-457 
inflammatory cytokine (IL-10) in striatal tissue via a bead-based immunoassay. One-458 
way ANOVA analyses revealed significant differences in cytokine expression 459 
between treatment groups for TNFα (F(3,28)=3.675, p<0.05; Fig. 6A) and IL-1β 460 
(F(3,26)=3.806, p<0.05; Fig. 6B) but not IL-6 (F(3,28)=2.683, p=0.0659; Fig. 6C) and IL-461 
10 (F(3,28)=1.527, p=0.2293; Fig. 6D). Post hoc analyses demonstrated that TNFα 462 
(p<0.05) and IL-1β (p<0.05) expression were significantly decreased in HU-308 463 
treated mice when compared to control mice. Collectively these results indicate a 464 
treatment dependent reduction in pro-inflammatory but not in anti-inflammatory 465 





Figure 6. HU-308 treatment attenuates pro-inflammatory cytokine expression in 468 
the striatum of LID mice. HU-308 treatment significantly reduced (A) TNFα and (B) 469 
IL-1β expression, while no treatment regime had a significant effect on (C) IL-6 or 470 
(D) IL-10 expression as measured by bead-based immunoassay. All values 471 






3.2.3 Amantadine, HU-308 and combined treatment decreased NF-κB activity in 475 
the striatum of dyskinetic mice 476 
The activity of the transcription factor NF-κB, a crucial regulator of the expression of 477 
several hundred target genes involved in inflammation and cell death, is upregulated 478 
in neuroinflammation. By measuring changes in expression of the phosphorylation 479 
site at Ser536, we aimed to determine increases in NF-κB activity across groups. 480 
One-way ANOVA analyses revealed significant differences of NF-κB(Ser536) 481 
(F(3,28)=7.759, p<0.001; Fig. 7D) but not the total NF-κB protein (F(3,28)=1.018, 482 
p=0.3995; Fig. 7B) between treatment groups. Post hoc analyses demonstrated that 483 
NF-κB(Ser536) was decreased in amantadine (p<0.001) and amantadine + HU-308 484 






Figure 7: Amantadine treatment attenuates NF-κB activity in the striatum of LID 488 
mice 489 
Representative pseudo bands generated by Wes of striatal (A) NF-κB and β-tubulin 490 
and (B) NF-κB(Ser536) and GAPDH expression. Western blotting quantification of 491 
(C) total NF-κB protein is unchanged in all groups, while (D) the NF-κB 492 
phosphorylation site Ser536 is significantly decreased in amantadine, HU-308 + 493 
amantadine treated mice when compared to control mice. All values represent the 494 











4. Discussion  503 
 504 
Throughout this study we have referred to the term neuroinflammation, which is 505 
classically defined by changes in glial proliferation, morphology and cytokine release, 506 
among other measures. However there has been an increasing recognition of the 507 
limitations of the term neuroinflammation and an increasing understanding of the 508 
multiple roles of glia in the healthy and diseased brain (Hammond et al., 2018; 509 
Khakh and Sofroniew, 2015; Morris et al., 2013). With this understanding, we and 510 
others have suggested that targeting glial homeostasis offers a promising route for 511 
treating neurodegenerative diseases and conditions in which synapse and neuron 512 
loss is implicated (Morris et al., 2013).  513 
 514 
Given the evidence of altered glial function and morphology associated with LIDs 515 
(Mulas et al., 2016), the presence of CB2 receptors on glia, and their apparent effect 516 
of reversing altered glial function and morphology, (Benito et al., 2008), we 517 
hypothesised targeting CB2 receptors could provide a potential avenue for 518 
attenuating dyskinesia. Using a mouse model of LIDs, the current study revealed 519 
three key findings. First, the CB2 selective agonist HU-308 dose-dependently 520 
reduced LID to the same magnitude as the current frontline treatment, amantadine. 521 
Second, treatment with HU-308 plus amantadine resulted in an additive anti-522 
dyskinetic effect. Third, these treatment regimens decreased the expression of 523 
neuroinflammatory mediators in the striatum of 6-OHDA lesioned mice. Our findings 524 
therefore provide the first evidence that targeting CB2 receptors may be a promising 525 





4.1 HU-308 dose-dependently reduced AIMs  528 
To favor drug safety and tolerability, and to avoid adverse effects, cannabinoid 529 
treatments are preferably administered at the lowest therapeutically efficacious dose 530 
(MacCallum and Russo, 2018). Thus, we first determined the dose-dependent effect 531 
of HU-308 on reducing AIMs in a mouse model of LID. Our results suggest that 532 
2.5mg/kg and 5mg/kg of HU-308 were able to reduce dyskinesia’s to a similar extent, 533 
which is greater than that seen with 1mg/kg HU-308. Collectively, these results allow 534 
us to conclude that 2.5mg/kg HU-308 is an efficacious dose that achieves maximum 535 
reduction of AIMs in mice.  536 
4.2 The anti-dyskinetic effect of HU-308 was CB2 specific  537 
One major caveat for the therapeutic development of cannabinoids are the unwanted 538 
psychoactive side-effects associated with CB1 agonism (Pacher et al., 2006). A CB2 539 
agonist offers a desirable alternative as it does not appear to trigger these side-540 
effects (Tabrizi et al., 2016). HU-308 has previously been shown to be a CB2 541 
specific agonist, efficiently binding to CB2 (Ki = 22.7), while not binding to CB1 (Ki > 542 
10 μM) (Hanus et al., 1999). In order to test receptor specificity of drugs, it is 543 
common practice to demonstrate a lack of effect in receptor knockout animals. 544 
Although there are multiple CB2 knockout mouse lines available (Buckley et al., 545 
2000; Li and Kim, 2016), CB2 lacking mice may be more susceptible to toxins, as 546 
evidenced by an increase in lesion severity in the LPS mouse model of PD (Gómez-547 
Gálvez et al., 2016). Thus, the lesion size following 6-OHDA treatment would likely 548 
be larger in CB2 knockouts compared to wildtype controls which would affect the LID 549 
magnitude and make results difficult to interpret. Accordingly, as a consistent lesion 550 
volume is critical for our LID studies we were unable to use these genetically 551 




specificity by determining if the selective CB2 receptor antagonist SR144528 can 553 
block the anti-dyskinetic effect of the CB2 receptor agonist HU-308 administered 554 
only after the lesion is created. This strategy has previously been used in a rat model 555 
of Huntington’s disease, with SR144528 blocking the neuroprotective effect of HU-556 
308 (Sagredo et al., 2009). As hypothesized, SR144528 by itself had no effect on 557 
AIMs, but when administered in conjunction with HU-308, SR144528 fully blocked 558 
the anti-dyskinetic effect of HU-308. Together, these results allow us to conclude that 559 
HU-308’s anti-dyskinetic properties are CB2 specific and unlikely due to any off-560 
target effects. 561 
4.3 The anti-dyskinetic effect of HU-308 is comparable to that of amantadine 562 
After establishing the anti-dyskinetic efficacy of HU-308 we next aimed to compare 563 
the magnitude of this effect to that of amantadine. Others have previously reported 564 
that a dosage of 40mg/kg amantadine is close to the upper limit of its therapeutic 565 
efficacy in rodents (Brigham et al., 2018; Danysz et al., 1997). In our hands, 566 
amantadine at this dose resulted in a 30% reduction of AIMs and 45% reduction in 567 
FosB expression, which closely aligns with previous studies in 6-OHDA lesioned 568 
mice reporting the ability of amantadine to reduce both dyskinetic behavior (up to 569 
36%) (Sebastianutto et al., 2016) and FosB expression (up to 47%) (Doo et al., 570 
2014). This demonstrated the robustness of this model as a tool to detect 571 
improvements in LID symptoms. Remarkably, 2.5mg/kg HU-308 was as effective as 572 
amantadine and reduced AIMs by 31% and FosB expression by 50%. If it were to 573 
reproduce in human cohorts, pharmacologically targeting CB2 might provide a useful 574 
alternative to amantadine, for example in cases where there are amantadine specific 575 
side effects. In support of this, several CB2 selective agonists have shown to be 576 




treating peripheral pain and inflammatory conditions in Phase 1 and 2 clinical trials 578 
(Di Marzo, 2018; Tabrizi et al., 2016). Accordingly, clinical trials investigating their 579 
efficacy for neurodegenerative diseases is currently in high demand. 580 
4.4 HU-308 and amantadine have an additive anti-dyskinetic effect 581 
To maximize symptomatic relief it is common practice to treat patients with a 582 
combination of different drugs (Thorlund and Mills, 2012). This is particularly 583 
valuable where two drugs can act more effectively together such that the effect of the 584 
two drugs in combination can exceed the maximal effect of either drug used alone. 585 
We demonstrated that the anti-dyskinetic effect of HU-308 is dose-dependent, but 586 
maximal at 2.5mg/kg. It is striking, therefore, that we found the addition of 587 
amantadine to HU-308 treatment resulted in a greater magnitude of reduction in AIM 588 
scores compared with that maximally achieved with HU-308. This result could be 589 
taken to suggest that HU-308 and amantadine ultimately each modulate the 590 
expression of LIDs through different but synergistic pathways so that the combined 591 
effect of both exceeds that which can be achieved by HU-308 alone. Regardless, our 592 
result suggests a combined HU-308 and amantadine treatment may be of greater 593 
benefit for PD patients with LIDs than either alone. 594 
 595 
4.5 HU-308 and amantadine exert anti-inflammatory properties in striatal tissue 596 
In investigating the apparent effects of amantadine and HU-308 on glial responses in 597 
this study we have largely confirmed previous published findings. In particular, it has 598 
been reported that amantadine has effects on glia independently of its actions on 599 
NMDA receptors, and that this is associated with the protection of cultured DA 600 
neurons against MPP+ and LPS toxicity (Kim et al., 2012; Ossola et al., 2011) as 601 




2012). The latter study demonstrated amantadine treatment reduced microglia 603 
proliferation and decreased NF-κB activity (Kim et al., 2012). Our data confirms and 604 
advances these findings. Whereas previous studies focused on the impact of 605 
amantadine on neuroinflammation and related degeneration of dopaminergic 606 
neurons in the SNpc, we are the first to report that amantadine has the capability to 607 
reduce microglial proliferation, GFAP+ astrocytes and cytokine release in the 608 
striatum of dyskinetic mice.  609 
 610 
Our experiments also confirm the effect of HU-308 in striatal tissue, as previously 611 
demonstrated in Parkinson’s (Gómez-Gálvez et al., 2016) and Huntington’s 612 
(Palazuelos et al., 2009) disease mouse models. In particular, those studies 613 
demonstrated that HU-308 treated mice showed a reduction in microglial proliferaiton 614 
and GFAP+ astrocyte populations in an excitotoxic Huntington’s model (Palazuelos 615 
et al., 2009) and a reduction in activated microglia as well as reduced mRNA 616 
expression of the pro-inflammatory cytokines TNFα and IL-1β in an Parkinson’s 617 
model (Gómez-Gálvez et al., 2016). Accordingly, our results strengthen the 618 
hypothesis of an anti-inflammatory protential of HU-308 acrross multiple 619 
neurodegenerative disorders and models.  620 
 621 
4.6 HU-308 and amantadine did not exhibit an additive effect on 622 
neuroinflammation  623 
Despite finding that both HU-308 and amantadine exert significant effects on glia in 624 
our model, we did not find an additive effect of combined treatment. This finding is 625 
not surprising as we (Morris et al., 2014, 2013) and others (Hammond et al., 2018; 626 




astrocytes are far more complex than previously thought. For example we now know 628 
that activated microglia drive the activation of astrocytes (Liddelow et al., 2017), that 629 
there are unique subsets of glia with only a proportion impacting neurodegenerative 630 
diseases (Deczkowska et al., 2018; Jordão et al., 2019; Keren-Shaul et al., 2017; 631 
Masuda et al., 2019) and that immediate activation and proliferation of microglia after 632 
neuronal injury may favour recovery (Tay et al., 2018, 2017). Accordingly, 633 
amantadine and HU-308 could be acting on some of these glial cell functions, and 634 
our broad measurements of glial cell counts and cytokines measurements only 635 
provide a small snapshot of the effects occurring in glia in our model.  636 
 637 
Alternatively, the behavioural effect of each drug may be due, fully or in part, to 638 
effects of the drugs that are independent of their actions on dampening an 639 
inflammatory response associated with LIDs. For example, it has long been thought 640 
amantadine primarily suppresses LIDs via its weak NMDA antagonism (Blanpied et 641 
al., 2005; Paquette et al., 2012) on striatal neurons, which may be separate, 642 
additional to, or part of, its reported anti-inflammatory actions. Meanwhile, the well 643 
known presence of CB2 receptors on glia does not rule out a potential direct or 644 
indirect action on of CB2 receptor agonists at synapses. Indeed, activation of CB2 645 
receptors in the hippocampus for 7-10 days increases mEPSC frequency and spine 646 
density, suggesting CB2 receptors may also function to modulate synaptic activity 647 
(Kim and Li, 2015). The latter finding could result from an indirect action of CB2 648 
receptor activation on glia, since recent research suggests that glia regulate 649 





Our measures in this paper are too rudimentary to explore these various 652 
mechanisms, and much further research is needed. However, not withstanding this 653 
limitation, our data adds weight to the concept that agents that act on glia may 654 
provide a promising option in pre-clinical and clinical drug development for 655 
neurodegenerative diseases generally and for LIDs in particular. 656 
 657 
4.7 Strengths, limitations and future directions 658 
The current study had several strengths, supporting the robustness of our findings. 659 
First, we ensured that anti-dyskinetic effects were not due to coincidental allocation 660 
of mice with a lesser lesion into any one particular treatment group, by confirming TH 661 
levels in striatal tissue were not different between groups. Second, by conducting our 662 
study in mice with established LIDs (as described previously by us (Rentsch et al., 663 
2019) and others (Sebastianutto et al., 2016)), mice were distributed so that there 664 
was no coincidental allocation of mice with lower or higher average AIM score in one 665 
or another group prior to treatment. Lastly, our behavioural data were largely 666 
correlated to the expression of FosB, a widely used molecular marker of LID 667 
(Andersson et al., 1999; Lundblad et al., 2004; Winkler et al., 2002). However, while 668 
this marker is mostly reliable in detecting gross changes in dyskinesia severity 669 
(dyskinetic vs. non-lesioned) it is possible this marker is unable to detect subtle to 670 
moderate changes within animals that are expressing dyskinesia (Smith et al., 2012). 671 
This may explain the instances in which FosB expression did not precisely 672 
corroborate our behavioural findings. 673 
 674 
Our study also had limitations. As is often the case in preclinical research, our study 675 




potential efficacy of HU-308 has not yet been assessed in cohorts with different 677 
ages, sexes and strains. These are important next preclinical steps, before 678 
translation is considered. Furthermore, while cannabinoid treatments shape as 679 
promising therapeutic targets for motor disorders, an important caveat is that 680 
cannabinoids might also act as motor-depressants. However, these effects are 681 
generally thought to be mediated by CB1 signaling, rather than CB2, which was one 682 
of the primary reasons we were interested in pursuing a CB2 agonist in this study 683 
(Hanus et al., 1999). In confirmation of this, in a previous study, HU-308 did not 684 
affect general motor activity in an open field test, nor did it cause catalepsy in naïve 685 
mice, even when administered at high doses (Hanus et al., 1999). Nevertheless, it 686 
will be important to conclusively determine if HU-308 has any effect on general or PD 687 
and LID specific motor activity in future studies. Finally, LIDs can last for many years 688 
in patients and we therefore suggest that, based on the enticing results of the current 689 
study, future studies of CB2 agonists in dyskinesias should confirm efficacy over a 690 
greatly extended period. 691 
 692 
5. Conclusion 693 
 694 
Collectively, our findings suggest CB2 agonists offer a putative target to treat LIDs, 695 
with efficacy comparable to the frontline treatment amantadine. This behavioural 696 
effect is associated with an effect on glial signalling (as evidenced by downregulation 697 
of neuroinflammation), providing further evidence that therapeutics targeting 698 
neuroinflammation and/or glial homeostasis may provide benefit for combating LIDs. 699 
Furthermore, one of the more important findings was the demonstration on an 700 
additive effect of HU-308 and amantadine that is greater than that achieved with HU-701 
308 alone. Although we do not yet know the precise mechanisms driving this effect, 702 




important clinical implications. We have suggested several exciting future directions 704 
to investigate the mechanism by which amantadine and HU-308 may exert their 705 
effects, particularly exploring novel features of microglia and astrocyte physiology 706 
and pathophysiology and their direct and/or indirect impact on neuronal synaptic 707 
signalling which is known to be altered in dyskinesias. Our study suggests that 708 
targeting glial function may be an important strategy for developing therapies for 709 
treating LIDs, a major unmet need for PD patients.  710 
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